Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Audentes Therapeutics, Inc.

http://www.audentestx.com/

Latest From Audentes Therapeutics, Inc.

Audentes Set To Resume XLMTM Trial As US Hold Lifts

Trial of high-need gene therapy set to restart following the deaths of several participants and the lifting of a clinical hold imposed by the US FDA last year.

Gene Therapy Clinical Trials

Stockwatch: Innovative Therapies 2020 – A Commercial Odyssey

The development and commercialization of cell and gene therapies during a pandemic, with regulators and payers demanding more data on effect duration and safety, has resulted in headwinds. Added to manufacturing and clinical trial recruitment issues, investors’ patience has been strained.

Innovation Regenerative Medicine

AnGes Takes Gene Editor Emendo Into Fold For $258m

Japanese firm sees broad promise in already affiliated US bioventure’s platform tech that will help it become a more global player in genetic medicine.

Commercial Gene Therapy

Third Death In Audentes’ XLMTM Gene Therapy Trial

Astellas subsidiary says it “remains committed” to on-hold program in high-need disease despite fatal events.

Clinical Trials Gene Therapy
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Antisense, Oligonucleotides
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Other Names / Subsidiaries
    • Cardiogen Sciences, Inc.
UsernamePublicRestriction

Register